Pressure BioSciences Announces Commercial Release of the HUB880 Explorer

Ultra High-Pressure Instrument Expected toEnhance the Science and Commercial Applications of High Pressure Processing Studies for FoodQuality and Safety; Results Expected to Guide Development ofthe Company's Ultra Shear Technology Platform

SOUTH EASTON, MA / ACCESSWIRE / September 13, 2018 / PressureBioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in thedevelopment and sale of broadly enabling, pressure-based instruments, consumables,and platform technology solutions to the worldwide life sciences industry,today announced the sale of the first two instruments from its newest line ofhigh-pressure based instrument systems, the HUB880 Explorer.

Dr. Nate Lawrence, PBI's Vice President of Marketingand Sales, said: "We are delighted that the first customer for our new HUB880Explorer system is one of Japan's leading research institutes conductingresearch and development on agriculture and food. The institute's goal is toincrease the productivity and safety of agriculture and food, while reducingproduction costs. We expect the institute to use the HUB880 Explorer to studythe effects of high pressure on food processing and on a number of foodbornepathogens."

Dr. Lawrence continued: "We are equally pleased thatthe second system was recently purchased by the Public Health MicrobiologyLaboratory ("PHM Laboratory") at Tennessee State University ("TSU"). The PHM Laboratory'sgoal is to conduct research to better understand environmental and entericpathogens and spoilage organisms. The PHM Laboratory is studying the effects ofhigh-pressure processing ("HPP") on several of the more prevalent foodbornepathogens, including E. coli, Listeria, and Salmonella."

According to information on the PHM Laboratorywebsite, foodborne diseases cost an estimated 420,000 lives every year aroundthe globe and are collectively responsible for the loss of over 33 millionyears of healthy living annually. Additionally, one out of six Americansexperiences illnesses from these pathogens every year, leading to about 128,000hospitalizations and over 3,000 deaths annually.

Dr. Aliyar Fouladkhah is an Assistant Professor at TSUand Director of the PHM Laboratory. He and his team have used PBI'spressure-based instruments for several years, during which time they havegenerated multiple publications related to foodborne pathogens, food qualityand safety. Dr. Fouladkhah said: "I am really proud to know that, according toa report from the Centers for Disease Control and Prevention, the progress foodscientists have made in the development of safer and healthier foods has beenone of the top 10 public health achievements of the 20^th century. Itis unequivocally clear to me that the food science community will requireextensive innovative solutions and cutting-edge technologies for years to come.High-pressure processing is one such technology. Ultra Shear Technology ("UST")may be another."

Dr. Lawrence added: "Our collaboration with Dr.Fouladkhah and the PHML team has been very fruitful. Their publications usingPBI's pressure-based systems have been impactful and well received, especiallyin the foodborne disease area. With its ability to reach higher pressure levelsand accept larger sample sizes, we believe the new HUB880 Explorer will enable scientistsat public health, food science, microbiology, agriculture, and other suchresearch laboratories, as well as scientists involved in food processingtechnologies like HPP, to study the mechanisms by which pressure inactivates foodpathogens and spoilage organisms, which should lead to improvements in the HPParea, and to safer food. Because of this, we believe the HUB880 Explorer hasthe potential to add significantly to our revenue base in the foreseeable future."

Richard T. Schumacher, President and CEO of PBI, said:"PBI is expanding its efforts and commitment into two very different butrelated areas of the very large food equipment industry: (i) laboratory-scale,high-pressure based research instruments (e.g., the HUB880 Explorer) to helpscientists better understand the mechanisms by which high pressure caninactivate foodborne pathogens and spoilage organisms, which in turn shouldimprove the processing of food, resulting in safer and higher quality food forconsumers worldwide, and (ii) Ultra Shear Technology, a scalable foodprocessing method that can address the limitations of using HPP for food, suchas batch mode processing only, high cost, poor results on low acid foods, and arequirement for post-processed food to be refrigerated. This entry into the food equipment market ishighly complementary to our existing presence in the life sciences toolsindustry, as it provides exciting new opportunities for growth by using thetechnical, scientific, and operational expertise we acquired while working onour cutting-edge biological sample preparation equipment."

Mr. Schumacher concluded: "We recently released newson our patented Ultra Shear Technology platform, which combines high pressurewith intense shear forces, while minimizing exposure to damaging elevatedtemperatures. We also announced the award of close to $1 million dollars fromthe USDA to Ohio State University to fund the development of the UST platform,of which we will receive $318,000 for the design, development, and manufactureof the initial prototypes of the bench-top and floor model UST instruments. We believeUST can be used to process healthy, nutritious, great tasting beverages andliquid foods, with extended shelf-lives but no chemical additives. We alsobelieve that UST can play a significant role in other very large marketsegments, such as pharmaceuticals, nutraceuticals, cosmetics, paints, andindustrial lubricants."

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, PBIO is actively expanding the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc. to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Forward Looking Statements

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2017, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

For more information about PBI and this press release, please click on the following website link:

http://www.pressurebiosciences.com

Please visit us on Facebook, LinkedIn, and Twitter.

Investor Contacts:

Richard T. Schumacher, President and CEO
Nathan P. Lawrence, Ph.D., VP of Marketing and Sales
(508) 230-1828 (T)
(508) 230-1829 (F)

SOURCE: Pressure BioSciences, Inc.